High Dose Atorvastatin Decreases Cellular Markers of Immune Activation Without Affecting HIV-1 RNA Levels: Results of a Double-blind Randomized Placebo Controlled Clinical Trial
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.